Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
14626 | 759 | 43.1 | 93% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
317 | 3 | HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA | 39408 |
1927 | 2 | FGF21//FIBROBLAST GROWTH FACTOR//FIBROBLAST GROWTH FACTOR 21 | 5824 |
14626 | 1 | FGF21//FIBROBLAST GROWTH FACTOR 21//FGF 21 | 759 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | FGF21 | authKW | 3711124 | 16% | 75% | 123 |
2 | FIBROBLAST GROWTH FACTOR 21 | authKW | 2785088 | 12% | 77% | 90 |
3 | FGF 21 | authKW | 877258 | 3% | 84% | 26 |
4 | BETA KLOTHO | authKW | 595985 | 3% | 74% | 20 |
5 | FGF19 | authKW | 528105 | 4% | 41% | 32 |
6 | FIBROBLAST GROWTH FACTOR 21 FGF21 | authKW | 234059 | 1% | 73% | 8 |
7 | IBT PROTE NANOTECHNOL | address | 128733 | 1% | 80% | 4 |
8 | FIBROBLAST GROWTH FACTOR 19 | authKW | 121894 | 1% | 30% | 10 |
9 | KLB | authKW | 90515 | 0% | 75% | 3 |
10 | FGF21 RESISTANCE | authKW | 80459 | 0% | 100% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 11386 | 47% | 0% | 357 |
2 | Cell Biology | 1026 | 20% | 0% | 153 |
3 | Biochemistry & Molecular Biology | 503 | 25% | 0% | 187 |
4 | Nutrition & Dietetics | 187 | 5% | 0% | 36 |
5 | Medicine, Research & Experimental | 139 | 6% | 0% | 47 |
6 | Physiology | 117 | 5% | 0% | 40 |
7 | Gastroenterology & Hepatology | 82 | 4% | 0% | 30 |
8 | Biophysics | 71 | 5% | 0% | 35 |
9 | Pharmacology & Pharmacy | 13 | 5% | 0% | 40 |
10 | Medical Laboratory Technology | 12 | 1% | 0% | 7 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | IBT PROTE NANOTECHNOL | 128733 | 1% | 80% | 4 |
2 | MOL EVOLUT TEAM | 80459 | 0% | 100% | 2 |
3 | CHINESE AMER DIABET COMPLICAT | 55297 | 1% | 13% | 11 |
4 | AGR BIOL FUNCT GENE | 55215 | 1% | 15% | 9 |
5 | ABORAT INNOVAT BIOMED | 40230 | 0% | 100% | 1 |
6 | ABORAT TRANSLAT BIOMED | 40230 | 0% | 100% | 1 |
7 | AFFILIATED PEOPLES HOSP 6 ENDOCRINOL METBOL | 40230 | 0% | 100% | 1 |
8 | AFFILIATED PEOPLES HOSP 6SHANGHAI DIABET SH | 40230 | 0% | 100% | 1 |
9 | AMER DIABET COMPLICAT | 40230 | 0% | 100% | 1 |
10 | BIOCHEMIDIPAZ | 40230 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOLECULAR METABOLISM | 23652 | 2% | 4% | 14 |
2 | CELL METABOLISM | 15901 | 3% | 2% | 24 |
3 | FRONTIERS IN ENDOCRINOLOGY | 6893 | 1% | 2% | 10 |
4 | ENDOCRINOLOGY | 1621 | 4% | 0% | 32 |
5 | DIABETES | 1182 | 3% | 0% | 19 |
6 | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 1110 | 3% | 0% | 26 |
7 | CLINICAL ENDOCRINOLOGY | 1031 | 2% | 0% | 14 |
8 | CELL REPORTS | 775 | 1% | 0% | 8 |
9 | PHYSIOLOGICAL RESEARCH | 721 | 1% | 0% | 7 |
10 | VITAMINS AND HORMONES | 658 | 0% | 1% | 2 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FGF21 | 3711124 | 16% | 75% | 123 | Search FGF21 | Search FGF21 |
2 | FIBROBLAST GROWTH FACTOR 21 | 2785088 | 12% | 77% | 90 | Search FIBROBLAST+GROWTH+FACTOR+21 | Search FIBROBLAST+GROWTH+FACTOR+21 |
3 | FGF 21 | 877258 | 3% | 84% | 26 | Search FGF+21 | Search FGF+21 |
4 | BETA KLOTHO | 595985 | 3% | 74% | 20 | Search BETA+KLOTHO | Search BETA+KLOTHO |
5 | FGF19 | 528105 | 4% | 41% | 32 | Search FGF19 | Search FGF19 |
6 | FIBROBLAST GROWTH FACTOR 21 FGF21 | 234059 | 1% | 73% | 8 | Search FIBROBLAST+GROWTH+FACTOR+21+FGF21 | Search FIBROBLAST+GROWTH+FACTOR+21+FGF21 |
7 | FIBROBLAST GROWTH FACTOR 19 | 121894 | 1% | 30% | 10 | Search FIBROBLAST+GROWTH+FACTOR+19 | Search FIBROBLAST+GROWTH+FACTOR+19 |
8 | KLB | 90515 | 0% | 75% | 3 | Search KLB | Search KLB |
9 | FGF21 RESISTANCE | 80459 | 0% | 100% | 2 | Search FGF21+RESISTANCE | Search FGF21+RESISTANCE |
10 | FGFR1C | 80459 | 0% | 100% | 2 | Search FGFR1C | Search FGFR1C |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | FISHER, FM , MARATOS-FLIER, E , (2016) UNDERSTANDING THE PHYSIOLOGY OF FGF21.ANNUAL REVIEW OF PHYSIOLOGY, VOL 78. VOL. 78. ISSUE . P. 223 -241 | 101 | 93% | 11 |
2 | DEGIROLAMO, C , SABBA, C , MOSCHETTA, A , (2016) THERAPEUTIC POTENTIAL OF THE ENDOCRINE FIBROBLAST GROWTH FACTORS FGF19, FGF21 AND FGF23.NATURE REVIEWS DRUG DISCOVERY. VOL. 15. ISSUE 1. P. 51 -69 | 129 | 56% | 13 |
3 | ZHANG, J , LI, Y , (2015) FIBROBLAST GROWTH FACTOR 21 ANALOGS FOR TREATING METABOLIC DISORDERS.FRONTIERS IN ENDOCRINOLOGY. VOL. 6. ISSUE . P. - | 99 | 93% | 4 |
4 | SO, WY , LEUNG, PS , (2016) FIBROBLAST GROWTH FACTOR 21 AS AN EMERGING THERAPEUTIC TARGET FOR TYPE 2 DIABETES MELLITUS.MEDICINAL RESEARCH REVIEWS. VOL. 36. ISSUE 4. P. 672 -704 | 126 | 70% | 1 |
5 | GIMENO, RE , MOLLER, DE , (2014) FGF21-BASED PHARMACOTHERAPY - POTENTIAL UTILITY FOR METABOLIC DISORDERS.TRENDS IN ENDOCRINOLOGY AND METABOLISM. VOL. 25. ISSUE 6. P. 303 -311 | 73 | 96% | 49 |
6 | KHARITONENKOV, A , DIMARCHI, R , (2015) FGF21 REVOLUTIONS: RECENT ADVANCES ILLUMINATING FGF21 BIOLOGY AND MEDICINAL PROPERTIES.TRENDS IN ENDOCRINOLOGY AND METABOLISM. VOL. 26. ISSUE 11. P. 608 -617 | 83 | 95% | 7 |
7 | ZHANG, FF , YU, LC , LIN, XF , CHENG, P , HE, LQ , LI, XK , LU, XM , TAN, Y , YANG, H , CAI, L , ET AL (2015) MINIREVIEW: ROLES OF FIBROBLAST GROWTH FACTORS 19 AND 21 IN METABOLIC REGULATION AND CHRONIC DISEASES.MOLECULAR ENDOCRINOLOGY. VOL. 29. ISSUE 10. P. 1400 -1413 | 92 | 88% | 5 |
8 | OWEN, BM , MANGELSDORF, DJ , KLIEWER, SA , (2015) TISSUE-SPECIFIC ACTIONS OF THE METABOLIC HORMONES FGF15/19 AND FGF21.TRENDS IN ENDOCRINOLOGY AND METABOLISM. VOL. 26. ISSUE 1. P. 22 -29 | 69 | 78% | 39 |
9 | MARKAN, KR , POTTHOFF, MJ , (2016) METABOLIC FIBROBLAST GROWTH FACTORS (FGFS): MEDIATORS OF ENERGY HOMEOSTASIS.SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY. VOL. 53. ISSUE . P. 85 -93 | 79 | 76% | 5 |
10 | KHARITONENKOV, A , ADAMS, AC , (2014) INVENTING NEW MEDICINES: THE FGF21 STORY.MOLECULAR METABOLISM. VOL. 3. ISSUE 3. P. 221 -229 | 70 | 89% | 42 |
Classes with closest relation at Level 1 |